Send email for updates


About updates
Research analysis

This entry is our account of a study selected by Drug and Alcohol Findings as particularly relevant to improving outcomes from drug or alcohol interventions in the UK. Links to other documents. Hover over for notes. Click to highlight passage referred to. Unfold extra text Unfold supplementary text

Title and link for copying Comment/query to editor

Concern over abstinence outcomes in Scotland's treatment services

A study of drug users starting treatment in Scotland revealed low rates of abstinence nearly three years later, findings which have been widely misinterpreted. The figures derived from the Drug Outcome Research in Scotland study (DORIS). Like NTORS in England, this sampled patients entering different types of treatments and observed their progress during and after normal treatment delivery.

The study's most significant outcome report to date documented the progress 33 months later of 695 (all who could be reinterviewed) out of 1033 people who started treatment in 2001.1 Though using other drugs, most saw their main problem as heroin. Abstinence was the sole drug use outcome reported, defined as totally avoiding drugs except alcohol or tobacco over the preceding three months. DORIS excluded from this designation anyone prescribed legal substitutes such as methadone.

On this criterion, overall just 8%2 of the sample were abstinent. For patients who had started treatment at detoxification or counselling services, it was 6%, for prison-based services, 5%, and for residential rehabilitation 25%, significantly higher than the other modalities.

No corresponding figure was presented for patients who started the study in methadone maintenance. Instead a figure was given for patients who had started methadone after their first DORIS treatment, about 3% of whom were abstinent. Another 8% confined their (non-alcohol, non-tobacco) drug use to prescribed methadone, meaning that 11% were no longer using illegal drugs. For residential rehabilitation this figure was 33%.

Abstinence was associated with positive outcomes in terms of social integration (education/employment and crime), self-perceived health and mental health. For example, 39% of non-abstinent (ex)patients had committed acquisitive crimes over the past 17 months compared to 9% who were abstinent, and 11% and 2% respectively had attempted suicide or harmed themselves.

These associations were said to underline "the benefits ... of drug users having an extended period of abstinence", implying that abstinence caused or enabled other improvements. Yet abstinence was measured over the past three months, associated " benefits" over the past 17. To establish causality, cause must be shown to come before effect. It seems equally conceivable that other life changes enabled abstinence or that there was a complex multi-way interaction. Also, an analysis based on drug use frequency or severity might have found similar improvements associated with less than total abstinence.

As DORIS researchers warned, potential caseload differences make it unsafe to assume that the various treatment modalities caused the associated differences in abstinence rates. Similar considerations led NTORS to avoid using statistical tests to compare the performances of different modalities because a level playing field in terms of caseload could not be assured.3 Since so few patients enter residential care in Scotland, and since selection procedures should ensure that this expensive option is reserved for those who could benefit most, it seems likely that they differ from the average methadone patient. Another complication is that in DORIS as in other studies, over the years patients traversed several treatment modalities, complicating the assessment of what led to the eventual outcomes.

Nevertheless the research has highlighted how few drug users enter residential rehabilitation in Scotland and how few become abstinent from illegal drugs after an episode in methadone maintenance, raising questions over the balance of investment in treatment modalities. However, for the reasons given above, it would be unsafe to reset the balance solely on the basis of these findings. Internationally, research on residential rehabilitation is sparse, methodologically weak and ambiguous about its benefits relative to less expensive treatment options, while that favouring methadone is more extensive and more convincing.4 5 6 Evidence for the special benefits of residential care is mainly confined to multiply problematic and more severe cases.7

For similar reasons it would be unsafe to assume that the findings support the diversion of methadone patients to services aimed at abstinence from illegal drugs and legal substitutes. Compared to well run methadone services, such services have been associated with an extremely high rate of relapse and resultant deaths because the short spell of abstinence has left patients unprotected by tolerance to opiate-type drugs yet failed to create the circumstances in which they could do without them.8

Rather than or in addition to rebalancing there may be a case for reviewing the resourcing of methadone treatment in Scotland and the services provided by the clinics. English figures show that nearly three times as much is spent on an episode of residential care as on an episode of methadone treatment.9 From its inception social reintegration has been a major benefit of effective methadone maintenance.10 In this and other respects, services vary widely. Among the critical factors are adequate, flexible dosing, procedures which minimise both drop-out and throw-out, sufficiently comprehensive services able to draw on wider social resources, staff committed to the welfare of patients and if indicated to indefinite maintenance, and good organisation.

In 2007 an official report on Scottish methadone services suspected that insufficient resources were devoted to rehabilitating patients, found patchy adherence to UK dosing guidelines, differing views on the desirability of long-term prescribing, and widely differing policies on supervised consumption.11 Such differences are bound to affect patient retention and outcomes and the possibilities for rehabilitation.

Thanks for their comments on this entry in draft to Neil McKeganey of the University of Glasgow, David Best of the University of Birmingham, Mike McCarron of the Scottish Alcohol and Drug Action Team Association, and the staff of Glasgow Addiction Services. They bear no responsibility for the text including the interpretations and any remaining errors.

1 FEATURED STUDY McKeganey N. et al. Abstinence and drug abuse treatment: results from the Drug Outcome Research in Scotland study. Drugs: Education, Prevention & Policy: 2006, 13(6), p. 537–550.

2 Probably fewer given the numbers not followed up. This applies also to other abstinence estimates.

3 Gossop M. et al. The National Treatment Outcome Research Study in the United Kingdom: six-month follow-up outcomes. Psychology of Addictive Behaviors: 1997, 11 (4), p.324–337.

4 Simoens S. et al. The effectiveness of treatment for opiate dependent drug users: an international systematic review of the evidence. Scottish Executive Effective Interventions Unit, 2002.

5 Drug misuse: psychosocial interventions. National Clinical Practice Guideline Number 51. National Collaborating Centre for Mental Health, 2007.

6 Mattick R.P. et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database of Systematic Reviews 2003, Issue 2.

7 Systematic but simple way to determine who needs residential care. Nugget 8.9. Drug and Alcohol Findings: 2003, 8, p. 13.

8 Best D. et al. Overdosing on opiates parts I and II. Drug and Alcohol Findings: 2000, issues 4 and 5.

9 Healey A. et al. Criminal outcomes and costs of treatment services for injecting and non-injecting heroin users: evidence from a national prospective cohort survey. Journal of Health Services Research and Policy: 2003 8, 134–141.

10 Ashton M. Methadone maintenance: the original. Drug and Alcohol Findings: 2006, issue 14.

11 Scottish Advisory Committee on Drug Misuse Reducing harm and promoting recovery: a report on methadone treatment for substance misuse in Scotland. SACDM, 2007.

Last revised 07 January 2008

Comment/query to editor
Give us your feedback on the site (one-minute survey)
Open Effectiveness Bank home page
Add your name to the mailing list to be alerted to new studies and other site updates


Top 10 most closely related documents on this site. For more try a subject or free text search

STUDY 2010 Long-term outcomes of aftercare participation following various forms of drug abuse treatment in Scotland

STUDY 2008 Helping drug treatment patients find work pays (some) dividends in Scotland

STUDY 2009 The Drug Treatment Outcomes Research Study (DTORS): final outcomes report

STUDY 2011 What is the role of harm reduction when drug users say they want abstinence?

STUDY 2004 Prison treatment in Scotland fails to impress

REVIEW 2017 An evidence review of the outcomes that can be expected of drug misuse treatment in England

MATRIX CELL 2014 Drug Matrix cell A2: Interventions; Generic and cross-cutting issues

DOCUMENT 2012 Medications in recovery: re-orientating drug dependence treatment

STUDY 2000 Force in the sunshine state

STUDY 2011 A good quality of life under the influence of methadone: a qualitative study among opiate-dependent individuals